Clinical Trial Update: Ponatinib for Squamous Cell Lung and Head and Neck Cancers [Phase 2, Phase 3]

View source ↗

Summary

Ponatinib was studied in Phase 2/Phase 3 trials for squamous cell carcinoma of the lung and head and neck squamous cell carcinoma. The studies were terminated a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Non-Small Cell Lung Cancer, Head and Neck Cancer | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2014-12-23